5Management of ‘refractory’ skin disease in patients with lupus erythematosus
Section snippets
Chronic cutaneous lupus erythematosus (CCLE)
CCLE can have several clinical manifestations. The most common subset is patients with DLE lesions. These patients might be classified as having localized DLE, when the lesions are only on the head and neck, or widespread DLE, when the lesions are on other body surfaces as well as the head and neck. Other, less common forms of chronic cutaneous LE include hypertrophic or verrucous (wart-like) lesions, lesions on the palms and/or soles, oral DLE, lupus tumidus, and lupus erythematosus
Subacute cutaneous lupus erythematosus (SCLE)
This subset is defined by the presence of skin lesions in which neither scarring nor atrophy occurs. In addition, follicular plugging is rarely observed in the lesions of SCLE. It is important to understand, however, that the patient in the SCLE subset can also have the scarring lesions of DLE, but these are not the predominant lesion. At least 50% of the patients with SCLE will have four or more features that classify them for a diagnosis of systemic LE. However, patients with SCLE differ from
Acute cutaneous lupus erythematosus (ACLE)
ACLE produces malar erythema, the classic ‘butterfly’ rash from which the term lupus erythematosus (wolf-like redness) was coined. The rash is induced by sun exposure or by exposure to other sources of ultraviolet light. Patients with a butterfly rash usually have active systemic disease, but there is no specific organ system involved.
Several cutaneous abnormalities had been part of the ACR criteria, but have been found to be less specific than photosensitivity. Diffuse hair loss (alopecia) was
Laboratory phenomena in patients with cutaneous LE
The full gamut of systemic disease manifestations of SLE can occur in patients with cutaneous disease, and thus these individuals can have any or all of the laboratory associations of the disorder. Serologic abnormalities are common in LE. They are more rare in patients with ‘pure’ cutaneous disease, such as DLE or HLE. The presence of abnormalities in these patients correlates with progressive disease or with the ACR criteria for SLE.7
The use of direct cutaneous immunofluorescence testing led
Management of cutaneous lupus erythematosus
Therapy of cutaneous lesions in patients with LE involves both an empiric as well as a scientific approach (Table 1).9, 10, 11, 12 Unfortunately, there are few double-blind, placebo-controlled trials of drugs utilized in the treatment of cutaneous LE. I generally approach patients with ‘specific’ lesions of LE in a similar manner when they have the relatively fixed lesions of subacute cutaneous LE (SCLE) (Figure 1) or chronic cutaneous LE manifest by discoid LE (DLE) lesions (Figure 2).
The
Conclusion
In summary, patients should be treated with sunscreens, protective clothing, behavioral alteration, topical corticosteroids, intralesional corticosteroids, and oral antimalarials as standard therapy. Attempts to reduce or stop smoking may aid in the control of cutaneous LE. The choice of alternative therapy is personal and discussions of the risks and benefits should be carefully documented. Successful therapy for cutaneous LE is possible in almost all well-motivated, cooperative patients.
References (78)
- et al.
Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation
Journal of the American Academy of Dermatology
(1990) - et al.
Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy
Human Pathology
(1997) - et al.
Pimecrolimus 1% cream for cutaneous lupus erythematosus
Journal of the American Academy of Dermatology
(2004) - et al.
Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment
Journal of the American Academy of Dermatology
(2000) - et al.
Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients
The Journal of Investigative Dermatology
(2002) - et al.
Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine
Journal of the American Academy of Dermatology
(1988) Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412
Journal of the American Academy of Dermatology
(1996)Management of skin disease in patients with lupus erythematosus
Best Practice and Research: Clinical Rheumatology
(2002)- et al.
Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus
Archives of Dermatology
(2003) How frequently are drugs associated with the development or exacerbation of subacute cutaneous lupus?
Archives of Dermatology
(2003)
Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: a review, with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual
International Journal of Dermatology
Photosensitivity in lupus erythematosus
Photodermatology, Photoimmunology and Photomedicine
The revised criteria for the classification of systemic lupus erythematosus
Arthritis and Rheumatism
Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence
Archives of Dermatology
Therapy of cutaneous lupus erythematosus
Dermatologic Therapy
Update on the management of cutaneous lupus erythematosus
The British Journal of Dermatology
Evidence-based evaluation of immunomodulatory therapy of cutaneous manifestations of lupus
Advances in Dermatology
Drugs for discoid lupus erythematosus
Cochrane Database of Systematic Reviews
Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy
Annals of Internal Medicine
Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases
Archives of Dermatology
Report of an association between discoid lupus erythematosus and smoking
Cutis
Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test
Photodermatology, Photoimmunology and Photomedicine
Use of sunscreens to protect against ultraviolet-induced lupus erythematosus
Arthritis and Rheumatism
Topical tacrolimus therapy of resistant cutaneous lesion in lupus erythematosus: a possible alternative
Rheumatology
Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus
Dermatology
Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod
Dermatology
Systemic lupus erythematosus arising during interferon-alpha therapy for cyroglobulinemic vasculitis associated with hepatitis C
Clinical Rheumatology
Discoid lupus erythematosus treated with cryotherapy
The Journal of Dermatological Treatment
Successful treatment of discoid lupus erythematosus with argon laser
Dermatology
Treatment of lupus erythematosus with pulsed dye laser
Lasers Surg Med
Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus
Journal of Rheumatology
The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus
Dermatology
Chloroquine-quinacrine association in resistant cutaneous lupus
Dermatology
The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients
Lupus
Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine
Eye
Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic and prognostic examination of 62 patients
Archives of Dermatology
Dapsone and discoid lupus erythematosus
The British Journal of Dermatology
Dapsone in the treatment of cutaneous lupus erythematosus
Dermatologica
Dapsone in the treatment of lupus erythematosus
British Journal of Dermatology
Cited by (26)
Pathogenesis of cutaneous lupus
2018, Dubois' Lupus Erythematosus and Related SyndromesRheumatologic Skin Disease
2015, Medical Clinics of North AmericaCitation Excerpt :Extension to photoprotected sites only rarely occurs. Because of its various nonlupus features, experts debate whether tumid lupus should be considered part of the lupus spectrum.3 Treatment of cutaneous lupus is based initially on severity, with attention later to clinical response and escalation of therapy for resistant disease (Fig. 5).
SER Consensus statement on the use of biologic therapy for systemic lupus erythematosus
2013, Reumatologia ClinicaThalidomide in cutaneous lupus erythematosus
2013, Seminarios de la Fundacion Espanola de ReumatologiaLupus Erythematosus
2009, Dermatological Signs of Internal Disease